Dr. John Summers, MD, FACC leads a panel discussion with Dr. Sanjaya Gupta, MD, FACC and Dr. Joseph Bumgarner, MD, FACC as they present some exciting, new information about the vascular closure space, specifically as it pertains to venous closure.  They will review the evolution of venous closure and focus on extravascular, sealant-based devices and the benefit they provide to physicians, staff, and patients.  Standards of care are shifting as procedures that require venous access are advancing; prolonged bedrest and overnight stays are no longer a gold standard. The results from the ReliaSeal trial and subsequent approval of MYNX CONTROL™ VENOUS Vascular Closure Device (VCD) pave the way for millions of patients to benefit from the quickest time to hemostasis and fastest sealant resorption of any venous closure device on the US market.  Adding to these unique benefits, MYNX CONTROL™ VENOUS VCD allows these physicians to confidently close the vessel with an easy-to-use, one-button deployment device. Listen in as these physicians speak to their experience using the device in the trial and discuss their plans to continue using MYNX CONTROL™ VENOUS now that it is on the market in the US.